For brand name Zytiga, Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.
According to the European Medicines Agency, brand name Zytiga originating from Europe is manufactured at the following site(s): Janssen-Cilag SpA Via C. Janssen Borgo San Michele I-04100 Latina, Italy
Information about Zytiga (Abiraterone)
Zytiga (abiraterone) is primarily used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). It functions by inhibiting the enzyme CYP17A1, which plays a crucial role in the production of androgens, including testosterone and other hormones that can promote cancer growth. By targeting this enzyme, Zytiga effectively reduces androgen levels in the body, which can help slow the progression of the disease.
The medication is typically used when other hormone therapies have not been effective. Zytiga is taken as an oral pill, and its dosage and administration are determined by a healthcare professional based on individual patient needs and responses to treatment. Regular monitoring and follow-up are essential to assess the drug's effectiveness and to adjust the treatment plan if necessary.
Product Highlights:
Zytiga is specifically designed for treating advanced prostate cancer that has not responded to standard hormone therapies. It helps manage the disease by lowering androgen levels, which can slow down cancer growth.
The medication works by inhibiting the enzyme CYP17A1, which is involved in the production of androgens like testosterone. This targeted approach helps to reduce hormone-driven cancer progression.
Zytiga is often used in conjunction with prednisone to enhance its therapeutic effects. Prednisone helps manage some of the effects related to reduced androgen levels, improving overall treatment outcomes.
Key Ingredient:
abiraterone acetate
Key Benefits:
Zytiga helps slow down or halt the progression of metastatic castration-resistant prostate cancer, potentially extending survival and improving disease control.
The medication can delay the onset of symptoms and the need for additional treatments by effectively managing the disease in advanced stages.
Zytiga can help alleviate symptoms associated with advanced prostate cancer, such as pain and discomfort, leading to an improved overall quality of life.
Direction of Use:
Take Zytiga exactly as prescribed by your healthcare provider. It is usually taken as one tablet, once daily, on an empty stomach. Avoid eating for at least 2 hours before and 1 hour after taking the medication.
Swallow the tablet whole with water. Do not chew, crush, or break the tablet, as this can affect how the medication is absorbed.
Take Zytiga at the same time each day to maintain a consistent level of the medication in your system. Follow the prescribed dose and schedule strictly, without skipping or doubling up on doses.
Condition
Dosage
Administration
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1,000 mg (one 1,000 mg tablet) daily
Taken orally once daily on an empty stomach
Safety Concerns:
Zytiga can affect liver function, so regular liver function tests are required to monitor for potential liver damage. Inform your healthcare provider of any symptoms like jaundice, dark urine, or abdominal pain.
Zytiga may interact with other medications, including over-the-counter drugs and supplements. Inform your healthcare provider of all medications and supplements you are taking to avoid potential interactions.
Zytiga can be harmful to an unborn baby. It is important for women who are pregnant or breastfeeding to avoid exposure to the drug, and men taking Zytiga should use effective contraception to prevent pregnancy.
Avoid Zytiga (Abiraterone) If:
you have a known allergy or hypersensitivity to abiraterone or any of its components, you should avoid using this medication.
you have severe liver problems or liver disease, Zytiga may not be suitable, as it can affect liver function.
you have high blood pressure that is not well-controlled, you should consult your healthcare provider, as Zytiga can potentially exacerbate this condition.
